Open-label treatment extension of ruxolitinib cream in vitiligo: findings from the TRuE-V long-term extension phase 3 study

We present data from the TRuE-V long-term extension (LTE) study evaluating repigmentation outcomes with continued ruxolitinib cream treatment in patients who did not achieve near-complete facial repigmentation in TRuE-V1/TRuE-V2. Among patients who applied ruxolitinib cream from TRuE-V1/TRuE-V2 Day 1, approximately 66% achieved F-VASI75 (indicative of treatment success) at Week 104, increasing from nearly 31% at Week 52 (TRuE-V LTE baseline); similar repigmentation improvements were reported in patients who switched from vehicle to ruxolitinib cream after TRuE V1/TRuE-V2 Week 24, albeit with lower overall response rates due to shorter duration of ruxolitinib cream application. These findings indicate that continued ruxolitinib cream treatment allows further repigmentation in many patients.